StockNews.AI
ONC
StockNews.AI
187 days

BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27

1. BeiGene, Ltd. to report Q4 2024 results on February 27, 2025. 2. Company is rebranding to BeOne Medicines to enhance its oncology focus. 3. Management will hold a live webcast discussing financial results. 4. BeiGene is expanding its portfolio of affordable cancer treatments globally. 5. The company employs nearly 11,000 staff across five continents.

Earnings
+3.34%Current Return
VS
+1.08%S&P 500
$223.3102/13 06:14 AM EDTEvent Start
$230.7702/14 12:56 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The rebranding may not significantly influence ONC's immediate market response. Previous name changes in biotech had mixed results.

How important is it?

Earnings reports and corporate rebranding potentially impact ONC's operational perception. The importance lies in financial performance and strategic direction.

Why Short Term?

Market reactions are typically immediate; financial results will be evaluated soon. Historical data shows quarterly results prominently affect short-term stock movements.

Related Companies

BEIGBGNEONC
SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with BeiGene management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/, https://hkexir.beigene.com/, https://sseir.beigene.com/. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company's website. About BeiGene BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter), Facebook and Instagram. Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene's plans, commitments, aspirations and goals related to BeiGene’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeiGene’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law.

Related News